← Companies|ProMIS Neurosciences
PM

ProMIS Neurosciences

PMN·NASDAQToronto CAFounded 200410 employees
Micro CapbiotechPublicNeurology
Platform: PMN310 AD
Market Cap
$0.1B
All Drugs
2
Clinical Trials
2
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (PMN)
Loading PMN stock data...
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
SuramavacamtenPMN-1658Phase 11siRNATROP-2FGFRiUCPNH
DoxafutibatinibPMN-8834Phase 11siRNAMDM2PCSK9iMG
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (2)
2026-03-19
Suramavacamten Interim
Dravet
Past
2030-05-04
Doxafutibatinib Interim
MG
Interim